Pancreatic AdenocarcinomaOBTCPANNCT03673423
Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer
An observational study of Pancreatic Adenocarcinoma, run by Ospedale San Raffaele at 1 site in Italy.
Trial summary
Assess the degree of vascular involvement is crucial in the diagnostic and therapeutic work-up of pancreatic cancer. NCCN resectability classification is used to stratify patients (in resectable, borderline resectable and non resectable) and is based on contrast-enhanced CT scan images. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Adenocarcinoma
- How many people
- 138 participants
- Where
- 1 siteItaly
- Study dates
- 5 Sep 2018to 5 May 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: 138 Consecutive patients, able to produce an informed consent, from 18 years of age, with a non-metastatic pancreatic adenocarcinoma assessed by a contrast-enhanced high-quality CT scan.
Who may be able to join
- Age > 18 years
- Non-metastatic pancreatic adenocarcinoma
- Availability of contrast enhanced CT scan with adequate quality. Section thickness must be <3 mm, according to NCCN recommendations
- Pathological confirmation of pancreatic adenocarcinoma by cytology/histology is not required at the time of enrolment, but it is needed before including the CT scan in the pool of exams to be evaluated.
- Signed informed consent
Who cannot join
- Evidence of metastatic disease
- Inadequate quality CT scan (non-respecting the NCCN recommendations)
- Absence of cytology/histology confirmation
- Refusal to participate in the study
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
Ospedale San Raffaele
Milan, 20132
Gianpaolo Balzano
About this study
Official title: Interobserver Variability In The Assessment Of Vascular Invasion In Pancreatic Cancer
Assess the degree of vascular involvement is crucial in the diagnostic and therapeutic work-up of pancreatic cancer. NCCN resectability classification is used to stratify patients (in resectable, borderline resectable and non resectable) and is based on contrast-enhanced CT scan images. Unfortunately evaluation of imaging tests may rely on some degree of subjective interpretation by observers implying a fundamental variation in patient's treatments and an irreproducibility of different center study results.
This is a multicenter diagnostic study on interobserver agreement on the resectability of pancreatic cancer based upon NCCN criteria.
Read more
The primary aim of the study will be the assessment of interobserver variability to define vascular invasion and resectability status on CT scans (according to the last version of the NCCN Classification).
One hundred and thirty eight consecutive patients, able to produce an informed consent, from 18 years of age, with a non-metastatic pancreatic adenocarcinoma assessed by a contrast-enhanced high-quality CT scan will be enrolled.
69 CT scan studies provided by the centers involved (High volume for pancreatic surgery) will be randomly selected from a pool of 138 of the patients that meet the inclusion criteria. Each study will be independently reviewed by a senior radiologist and a senior surgeon of each center, blinded to patient's clinical history and CT scan report, using NCCN definition of respectability status. A CFR will be filled during the review and send to the study coordinator. The data will be than centrally analyzed to asses interobserver agreement The enrolment phase will last 6 months and the whole study will last 8 months.
Read the detailed description
Pancreatic adenocarcinoma frequently invades peripancreatic major vessels (common hepatic artery, celiac axis, superior mesenteric artery and mesenteric-portal confluence), requiring vascular resection or precluding the possibility of a radical resection. To Asses local resectability in pancreatic cancer patients is a key step to the whole process of care and it can change dramatically the outcomes. It is also extremely important in the reproducibility of different scientific studies that stratified or included patients on this feature. Resectability status classification of pancreatic adenocarcinoma, according to the definition of the National Comprehensive Cancer Network (NCCN) is widely used in current surgical and oncological practice to define the degree of vascular invasion: this classification describes three different classes of tumor depending on the local extension and vascular involvement. Resectable cancers are defined when no contact with the main vessels can be detected, whereas borderline resectable and non resectable tumors have a different extent of vascular infiltration. The recommended staging exam to define vascular involvement of pancreatic adenocarcinoma is contrast-enhanced CT scan; NCCN recommends that all patients with suspicion of pancreatic adenocarcinoma have a dedicated pancreas protocol CT scan as part of the initial assessment. From the attribution of a patient to a resectability class (resectable, borderline resectable or non resectable) derives the choice of a specific therapeutic pathway, as suggested by NCCN guidelines. International validated criteria to define local respectability are available but they can be prone to subjective interpretation. An evaluation of interobserver agreement on local resectability for pancreatic cancer in a multicenter setting is needed to understand the reliability and reproducibility of this system.
The primary aim of the study will be the assessment of interobserver variability to define vascular invasion and resectability status on CT scans (according to the last version of the NCCN Classification).One senior radiologist and one senior surgeon from different Italian high-volume Institutions will separately assess the degree of vascular invasion by pancreatic cancer and the definition of resectability status according to NCCN. 69 CT scans, randomly selected from a pool of 138 studies (provided by each center and collected by the study coordinator) of non-metastatic consecutive patients with pancreatic cancers that signed the informed consent, will be evaluated. CT scans will be provided by participating centres, that will send them to the coordinating centre until reaching the planned enrolment. The images and related DVDs will be made anonymous and identified just by serial number and initials of the patient. The CT scan reports will be collected by each centre and made available by the coordinating centre for subsequent analysis. The criteria used to define the resectability status are those developed by the NCCN and included in the latest guidelines. Observers will be blinded to the CT-scan reports, as well as to the clinical history of the patient, and to the votes of the other raters. The degree of each vessel invasion and assignment of each tumor to a category of resectability status (resectable - borderline resectable - non resectable) will be defined separately by all raters, by fulfilling a template adopted and reported in NCCN guidelines. An interrater reliability analysis using the Kappa statistic will be performed to determine consistency among observers on the respectability status. The consistency among observer will be also evaluated for each point of the criteria and section of the template to asses vascular involvement in detail.
In case of significant fair or poor agreement (K < 0.50), the participating raters (consensus group), including the study coordinator, will meet to discuss the cases that will have less than 100% agreement among all the raters. Scans will be reviewed, an open discussion ensued. Based on the discussion, the consensus group will develop proposals to address the specific areas of disagreement. The CT scans not select for the first evaluation will be than evaluated, using the proposal of the consensus group by a new set of rater (one senior radiologist and one senior surgeon from each institution involved) and the new Kappa statistic will be calculated.
- Conditions
- Pancreatic Adenocarcinoma
- Keywords
- Resectability Status, NCCN criteria
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment of interobserver variability to define vascular invasion and resectability status on CT scans
The primary aim of the study will be the assessment of interobserver variability to define vascular invasion and resectability status on CT scans (according to the last version of the NCCN Classification).
Measured: Eight months
Secondary outcomes (1)
Identification of disagreement causes and proposal of a new classification system
In case of significant low agreement (K < 0,5), causes of disagreement will be assessed and a new classification of vascular involvement will be proposed to reduce the disagreement. The new classification will be validated on the remaining 69 CT scans
Measured: One year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Sep 2018
- Study start5 Sep 2018
- Primary completion5 Mar 2019 (estimated)
- Study completion5 May 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic AdenocarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 138 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ospedale San Raffaele
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gianpaolo Balzano, Ospedale San Raffaele
- Investigators
- Gianpaolo Balzano, MD, Principal investigator, Ospedale San Raffaele
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03673423
- Sponsor's protocol ID
- OBTCPAN
- Acronym
- OBTCPAN
- Status last verified
- Dec 2018
- First submitted
- 12 Sep 2018
- Last updated
- 13 Dec 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Dec 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Interobserver Variability In The Assessment Of Vascular Invasion In Pancreatic Cancer
- ClinicalTrials.gov ID
- NCT03673423
- Acronym / sponsor ID
- OBTCPAN / OBTCPAN
- Conditions
- Pancreatic Adenocarcinoma
- Keywords
- Resectability Status, NCCN criteria
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 138 participants (estimated)
- Lead sponsor
- Ospedale San RaffaeleUniversity, hospital or other
- Study start
- 5 Sep 2018 (actual)
- Primary completion
- 5 Mar 2019 (estimated)
- Study completion
- 5 May 2019 (estimated)
- First posted
- 17 Sep 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Assess the degree of vascular involvement is crucial in the diagnostic and therapeutic work-up of pancreatic cancer. NCCN resectability classification is used to stratify patients (in resectable, borderline resectable and non resectable) and is based on contrast-enhanced CT scan images. Unfortunately evaluation of imaging tests may rely on some degree of subjective interpretation by observers implying a fundamental variation in patient's treatments and an irreproducibility of different center study results.
This is a multicenter diagnostic study on interobserver agreement on the resectability of pancreatic cancer based upon NCCN criteria.
The primary aim of the study will be the assessment of interobserver variability to define vascular invasion and resectability status on CT scans (according to the last version of the NCCN Classification).
One hundred and thirty eight consecutive patients, able to produce an informed consent, from 18 years of age, with a non-metastatic pancreatic adenocarcinoma assessed by a contrast-enhanced high-quality CT scan will be enrolled.
69 CT scan studies provided by the centers involved (High volume for pancreatic surgery) will be randomly selected from a pool of 138 of the patients that meet the inclusion criteria. Each study will be independently reviewed by a senior radiologist and a senior surgeon of each center, blinded to patient's clinical history and CT scan report, using NCCN definition of respectability status. A CFR will be filled during the review and send to the study coordinator. The data will be than centrally analyzed to asses interobserver agreement The enrolment phase will last 6 months and the whole study will last 8 months.
Detailed description
Pancreatic adenocarcinoma frequently invades peripancreatic major vessels (common hepatic artery, celiac axis, superior mesenteric artery and mesenteric-portal confluence), requiring vascular resection or precluding the possibility of a radical resection. To Asses local resectability in pancreatic cancer patients is a key step to the whole process of care and it can change dramatically the outcomes. It is also extremely important in the reproducibility of different scientific studies that stratified or included patients on this feature. Resectability status classification of pancreatic adenocarcinoma, according to the definition of the National Comprehensive Cancer Network (NCCN) is widely used in current surgical and oncological practice to define the degree of vascular invasion: this classification describes three different classes of tumor depending on the local extension and vascular involvement. Resectable cancers are defined when no contact with the main vessels can be detected, whereas borderline resectable and non resectable tumors have a different extent of vascular infiltration. The recommended staging exam to define vascular involvement of pancreatic adenocarcinoma is contrast-enhanced CT scan; NCCN recommends that all patients with suspicion of pancreatic adenocarcinoma have a dedicated pancreas protocol CT scan as part of the initial assessment. From the attribution of a patient to a resectability class (resectable, borderline resectable or non resectable) derives the choice of a specific therapeutic pathway, as suggested by NCCN guidelines. International validated criteria to define local respectability are available but they can be prone to subjective interpretation. An evaluation of interobserver agreement on local resectability for pancreatic cancer in a multicenter setting is needed to understand the reliability and reproducibility of this system.
The primary aim of the study will be the assessment of interobserver variability to define vascular invasion and resectability status on CT scans (according to the last version of the NCCN Classification).One senior radiologist and one senior surgeon from different Italian high-volume Institutions will separately assess the degree of vascular invasion by pancreatic cancer and the definition of resectability status according to NCCN. 69 CT scans, randomly selected from a pool of 138 studies (provided by each center and collected by the study coordinator) of non-metastatic consecutive patients with pancreatic cancers that signed the informed consent, will be evaluated. CT scans will be provided by participating centres, that will send them to the coordinating centre until reaching the planned enrolment. The images and related DVDs will be made anonymous and identified just by serial number and initials of the patient. The CT scan reports will be collected by each centre and made available by the coordinating centre for subsequent analysis. The criteria used to define the resectability status are those developed by the NCCN and included in the latest guidelines. Observers will be blinded to the CT-scan reports, as well as to the clinical history of the patient, and to the votes of the other raters. The degree of each vessel invasion and assignment of each tumor to a category of resectability status (resectable - borderline resectable - non resectable) will be defined separately by all raters, by fulfilling a template adopted and reported in NCCN guidelines. An interrater reliability analysis using the Kappa statistic will be performed to determine consistency among observers on the respectability status. The consistency among observer will be also evaluated for each point of the criteria and section of the template to asses vascular involvement in detail.
In case of significant fair or poor agreement (K < 0.50), the participating raters (consensus group), including the study coordinator, will meet to discuss the cases that will have less than 100% agreement among all the raters. Scans will be reviewed, an open discussion ensued. Based on the discussion, the consensus group will develop proposals to address the specific areas of disagreement. The CT scans not select for the first evaluation will be than evaluated, using the proposal of the consensus group by a new set of rater (one senior radiologist and one senior surgeon from each institution involved) and the new Kappa statistic will be calculated.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- 138 Consecutive patients, able to produce an informed consent, from 18 years of age, with a non-metastatic pancreatic adenocarcinoma assessed by a contrast-enhanced high-quality CT scan.
Key inclusion criteria (5 listed)
- Age > 18 years
- Non-metastatic pancreatic adenocarcinoma
- Availability of contrast enhanced CT scan with adequate quality. Section thickness must be <3 mm, according to NCCN recommendations
- Pathological confirmation of pancreatic adenocarcinoma by cytology/histology is not required at the time of enrolment, but it is needed before including the CT scan in the pool of exams to be evaluated.
- Signed informed consent
Key exclusion criteria (4 listed)
- Evidence of metastatic disease
- Inadequate quality CT scan (non-respecting the NCCN recommendations)
- Absence of cytology/histology confirmation
- Refusal to participate in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Assessment of interobserver variability to define vascular invasion and resectability status on CT scans
Time frame: Eight months
The primary aim of the study will be the assessment of interobserver variability to define vascular invasion and resectability status on CT scans (according to the last version of the NCCN Classification).
1 secondary outcome
Identification of disagreement causes and proposal of a new classification system
Time frame: One year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Dec 2018.
- Individual participant dataSharing planned: No
Related trials for Pancreatic Adenocarcinoma
Active, not recruitingPhase 1/2
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
RecruitingPhase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer
RecruitingPhase 2
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
Active, not recruitingPhase 1
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Breast Cancer, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gianpaolo Balzano, MD principal investigator
Ospedale San Raffaele
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreatic Adenocarcinoma, run by Ospedale San Raffaele at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 13 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Fabio Giannone, MD (+3903401036108, giannone.fabio@hsr.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment of interobserver variability to define vascular invasion and resectability status on CT scans (time frame: Eight months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Dec 2018.